Anti-thrombotic, anti-platelet and fibrinolytic therapy: current management of acute myocardial infarction

Simple item page
dc.contributor.authorHelft, G.
dc.contributor.authorWorthley, S.
dc.date.issued2001
dc.descriptionThe definitive version is available at www.blackwell-synergy.com
dc.description.abstractSignificant advances in the treatment of patients with acute myocardial infarction (MI) have been obtained in recent times. In particular, thrombolytic therapy has been shown to preserve ventricular function and improve survival in patients with acute MI. Therapies now include third-generation thrombolytic agents, percutaneous transluminal coronary angioplasty (PTCA) and intracoronary stenting, and new anti-thrombotic therapies including anti-platelet treatment with glycoprotein (GP) IIb/IIIa inhibition and direct anti-thrombin agents. This review will focus on the use of GP IIb/IIIa antagonists and thrombin inhibitors as adjunctive therapies to thrombolytic treatment of patients with acute MI.
dc.description.statementofresponsibilityGerard Helft and Stephen G. Worthley
dc.identifier.citationHeart Lung and Circulation, 2001; 10(2):68-74
dc.identifier.doi10.1046/j.1444-2892.2001.00086.x
dc.identifier.issn1443-9506
dc.identifier.urihttp://hdl.handle.net/2440/39093
dc.language.isoen
dc.publisherBlackwell Publishing Asia
dc.source.urihttp://www.blackwell-synergy.com/doi/abs/10.1046/j.1444-2892.2001.00086.x
dc.subjectanti-thrombotic therapy
dc.subjectmyocardial infarction
dc.subjectthrombosis
dc.titleAnti-thrombotic, anti-platelet and fibrinolytic therapy: current management of acute myocardial infarction
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications